Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

RNA Editing02:23

RNA Editing

10.2K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
10.2K
Experimental RNAi02:15

Experimental RNAi

8.4K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.4K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

3.3K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.3K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.1K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.1K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.2K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Zuranolone: First Approval.

Drugs·2023
Same author

Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

Drugs·2023
Same author

Birch Bark Extract: A Review in Epidermolysis Bullosa.

Drugs·2023
Same author

Flotufolastat F 18: Diagnostic First Approval.

Molecular diagnosis & therapy·2023
Same author

Omidubicel: First Approval.

Molecular diagnosis & therapy·2023
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
查看所有相关文章

相关实验视频

Updated: Apr 9, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.1K

阿帕达姆塔斯阿尔法:第一次批准

Young-A Heo1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|February 28, 2024
PubMed
概括
此摘要是机器生成的。

复合ADAMTS13酶阿帕达马酶α现在已在美国批准用于治疗先天性血栓性血栓性缺血性紫外线 (TTP). 这标志着对TTP患者的酶替代疗法的重大进展.

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Author Spotlight: Enhanced Murine AAA Model Using Elastase to Mimic Human Aneurysms
07:42

Author Spotlight: Enhanced Murine AAA Model Using Elastase to Mimic Human Aneurysms

Published on: July 26, 2024

1.5K

相关实验视频

Last Updated: Apr 9, 2026

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.1K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Author Spotlight: Enhanced Murine AAA Model Using Elastase to Mimic Human Aneurysms
07:42

Author Spotlight: Enhanced Murine AAA Model Using Elastase to Mimic Human Aneurysms

Published on: July 26, 2024

1.5K

科学领域:

  • 生物化学 生物化学
  • 血液学 血液学 血液学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 血栓性血栓塞性紫外线 (TTP) 是一种罕见的血液疾病,其特征是微血管病性血清性贫血,血栓塞性衰竭和器官损伤.
  • 缺少ADAMTS13 (一种具有血栓胺基因的分解蛋白和金属蛋白酶13) 是先天性TTP的根本原因.
  • 目前对先天性TTP的治疗选择有限,这凸显了需要有效的酶替代疗法.

研究的目的:

  • 总结一下阿帕达马酶α的发展里程碑,这是一个重组ADAMTS13酶.
  • 值得强调的是,美国FDA最近批准了阿帕达马酶α用于先天性TTP.
  • 为其他TTP形式和状细胞疾病提供正在进行的临床开发的概述.

主要方法:

  • 对阿帕达玛酶α的临床前和临床开发数据的审查.
  • 对监管提交和批准流程的分析.
  • 治疗应用和正在进行的研究的总结.

主要成果:

  • 阿帕达马酶α (复合-krhn;ADZYNMA) 是人类复合形式的ADAMTS13.
  • 2023年11月9日,阿帕达马酶α获得美国FDA的批准,用于先天性TTP的预防性和按需酶替代疗法 (ERT).
  • 该药物还在欧盟和日本对先天性TTP进行监管审查,并针对免疫介导的TTP和状细胞疾病进行临床开发.

结论:

  • 美国对阿帕达马酶α的批准代表了先天性TTP患者的显著治疗进步.
  • 阿帕达马酶α为管理TTP提供了一个新的酶替代疗法选择.
  • 目前正在进行进一步的临床开发,以探索其在其他相关血液病症中的有效性.